The KLOW blend is a synergistic lyophilized peptide formulation comprising four bioactive compounds—KPV (Lys-Pro-Val, a C-terminal tripeptide of α-melanocyte-stimulating hormone), BPC-157 (Body Protection Compound-157, a 15-amino acid gastric pentadecapeptide), TB-500 (a synthetic 43-amino acid fragment of thymosin β4), and GHK-Cu (glycyl-L-histidyl-L-lysine copper, a natural tripeptide chelated with copper)—designed for preclinical research into accelerated tissue repair, inflammation modulation, and regenerative processes. KPV exerts potent anti-inflammatory effects by downregulating pro-inflammatory cytokines (e.g., TNF-α, IL-6) and NF-κB pathways via melanocortin receptor activation, while enhancing epithelial barrier integrity and antimicrobial activity, particularly in models of colitis, dermatitis, and intestinal permeability. BPC-157 promotes angiogenesis, tendon/ligament healing, and gastrointestinal protection through upregulation of growth factors like VEGF and modulation of nitric oxide systems, counteracting tissue damage in injury and inflammatory models. TB-500 facilitates cellular migration, actin sequestration, and extracellular matrix remodeling to support wound closure, muscle recovery, and anti-fibrotic responses, with additional roles in immune cell trafficking and nitric oxide-mediated vasodilation. GHK-Cu influences over 4,000 genes associated with tissue remodeling, stimulating collagen/elastin synthesis, antioxidant defenses, and copper-dependent enzymatic activity to foster skin rejuvenation, vascular proliferation, and oxidative stress mitigation. Collectively, these peptides target complementary pathways—early inflammation control (KPV, BPC-157), cellular motility and structural repair (TB-500, GHK-Cu), and long-term remodeling (GHK-Cu, BPC-157)—yielding enhanced outcomes in experimental paradigms of wound healing, musculoskeletal injury, skin aging, and immune dysregulation, though human clinical data remain limited and further mechanistic studies are warranted.